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The Translocator Protein (TSPO), has been first identified in 1977 as binding site 
for the benzodiazepine diazepam in peripheral tissues (PBR). The early 
characterization of these “diazepam binding sites” outside the brain led to their 
nomination as “Peripheral-type benzodiazepine receptor”, to distinguish them 
from the central benzodiazepine receptor (CBR) which is part of the γ-
aminobutyric acid (GABA) type A (GABAA) receptor complex
1,2. Benzodiazepines 
widespread use in clinic is based upon potent anxiolytic, anticonvulsivant, 
hypnotic, muscle-relaxant and sedative properties, actions mediated by CBR that 
is restricted to the central nervous system (CNS)3. 
In 2006, Papadopoulos and co-workers4 renamed the PBR to Translocator 
Protein (18 kDa), with the abbreviation “TSPO”. The renaming of this protein was 
thought to represent more accurately findings regarding its structure, subcellular 
roles and putative functions. Further review of the current literature highlights 
the following key reasons and rationale that support this name change for the 
PBR. 
(i) The term ‘benzodiazepine’ is inaccurate because many ligands of other 
structures, such as cholesterol and protoporphyrin IX, also bind to the PBR. In 
addition, not all benzodiazepines bind to the PBR, so that including 
‘benzodiazepine’ in the nomenclature is potentially misleading and inaccurate.  
(ii) The term ‘peripheral-type’ does not reflect the real tissue distribution of 
the PBR because it is also expressed in glial and ependymal cells, which are 
located in the CNS.  
(iii) The PBR protein itself is not a receptor in the traditional sense. Cellular 
localization is usually, even though not always, mitochondrial. Although some 
data indicate that extra mitochondrial localizations of the PBR could result from 
mutations, there are no data indicating common functions of the nuclear and 
mitochondrial fractions. 
(iv) The term ‘binding site’ does not define the function with adequate 
specificity; binding per se does not reflect the importance of the protein or 
receptor, and it is too general term. 
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(v) Although ‘receptor’ functionality is appealing in the context of cell 
signalling, it might not be an optimal descriptor given the diverse nature of 
candidate physiological and pharmacological ligands and the currently 
incomplete understanding of the potential role of the PBR protein in the 
transduction of cell signals. 
There are three main Structure Activity Relationships (SAR) for the TSPO: (i) 
cholesterol binding and transport; (ii) protein import; and (iii) porphyrin binding 
and transport. Given all of these considerations, the expert panel reached a 
consensus to recommend renaming the PBR to TSPO.4 
The TSPO is an evolutionarily well-conserved 18 kDa protein consisting of 169 
amino acids,2 which is mainly located at the contact sites between the outer and 
inner mitochondrial membranes,5 although it is also expressed at low levels in 
other subcellular compartments, such as plasma membranes and nuclear 
fraction of cells.4 In mitochondria, the three-dimensional structure of TSPO, 
which is highly hydrophobic and rich in tryptophan, is characterized by five α-
helices spanning through the phospholipids bilayer of the mitochondrial 
membrane. Photolabelling studies indicated that this receptor is strictly 
associated in a trimeric complex with the 32 kDa voltage-dependent anion 
channel (VDAC) and the 30 kDa adenine nucleotide translocase (ANT), to 
constitute the mitochondrial permeability transition pore (MPTP), Figure 1. 
 
 
 
 
 
 
Figure 1. Translocator Protein.
4
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To date, four cytosolic TSPO interacting proteins have been identified, the 
function of two of them being unknown: PRAX-1, which interacts with the C-
terminal end of TSPO and p10, a 10 kDa protein which was co-
immunoprecipitated with the TSPO, but whose identity has not been unravelled.6 
The two other TSPO partners are the steroidogenic acute regulatory protein, 
StAR, which binds cholesterol and promotes mitochondrial cholesterol transfer7 
and PKA-associated protein 7, PAP7, which regulates steroidogenesis as shown in 
antisense and overexpression studies.6,8 
Varieties of endogenous molecules with different chemical structures that bind 
to TSPO have been identified. Among these, the main endogenous ligands 
include protoporphyrins (protoporphyrin IX, mesoporphyrin IX, 
deuteroporphyrin IX, hemin), phospholipase A2 (PLA2), diazepam binding 
inhibitor (DBI), and its biologically active derivatives.9 Cholesterol is also 
considered an endogenous nanomolar affinity ligand for TSPO. 
TSPO is widely expressed throughout the body, with higher levels in steroid 
producing tissues, but also in other peripheral tissues including liver, heart, 
kidney, lung, immune system. In the CNS, TSPO is mainly located in glial and 
ependymal cells.4 
TSPO is involved in a variety of biological processes including cholesterol 
transport, steroidogenesis, calcium homeostasis, lipid metabolism, mitochondrial 
oxidation, cell growth and differentiation, apoptosis induction, and regulation of 
immune functions.10,11 
 
 
TSPO and Regulation of Steroidogenesis 
Biosynthesis of tissue specific steroids typically involves the conversion of 
cholesterol into pregnenolone, which occurs through cholesterol side chain 
cleavage by cytochrome P450 enzyme (P450scc) and auxiliary electron 
transferring proteins, localized on the inner mitochondrial membrane. 
Cholesterol transport from the outer to the inner mitochondrial membrane is the 
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rate-determining step in steroid and bile acid syntheses.12,13 Widespread studies 
on the location and function of TSPO have found its role to be primarily involved 
in the cholesterol transport through the mitochondrial membranes and thus in 
the steroid synthesis. Cholesterol transport from the outer to the inner 
mitochondrial membrane is activated by specific ligand binding to TSPO, after 
which cholesterol undergoes metabolism and begins the steroidogenesis 
cascade.4 Cholesterol may interact with a receptor binding site on the C-terminus 
of the TSPO14, triggering its transport from the outer to the inner mitochondrial 
membranes.13,15 In the inner mitochondrial membrane, cholesterol is converted 
to pregnenolone by the C27 cholesterol side chain cleavage cytochrome P450 
enzyme (P450scc), that catalyses a series of reactions involving the formation of 
the 22R-hydroxycholesterol and 20,22R-hydroxycholesterol intermediates, 
followed by cleavage of the bond between C20 and C22. Pregnenolone then 
leaves the mitochondrion to undergo enzymatic transformation in the 
endoplasmic reticulum that will give rise to the final steroid products,16 Figure 2. 
 
 
Figure 2. Cholesterol metabolism in hepatic and steroidogenic cells. Cholesterol binds to TSPO 
and its transported up on binding of endozepine also called DBI. In hepatic cells, cholesterol is 
hydroxylated by cytochrome P450 (CYP27A1) to give 27-hydroxycholesterol, whereas in 
steroidogenic cells, cholesterol is cleavage by another cytochrome P450 (CYP11A1) that cleave 
side chain to give pregnenolone. 
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TSPO and Apoptosis 
The apoptotic cascade leading to cell death has been well characterized and in 
this process the dissipation of the mitochondrial transmembrane potential 
caused by the opening of the MPTP represent a critical initiating event. The 
resulting increased volume in the mitochondrial matrix leads to the disruption of 
the outer membrane integrity and the release of intermembrane proteins from 
the mitochondria. These proteins include cytocrome c and the apoptosis 
inducing factor, AIF. The AIF is a flavoprotein that translocates to the nucleus 
where it induces nuclear chromatin condensation and a large scale DNA 
fragmentation. In the cytosol, the cytochrome c interacts with Apaf-1 (apoptosis 
activating factor 1) and pro-caspase 9, leading to the activation of caspase 9, 
which in turn cleaves pro-caspase 3 to yield active caspase 3. This caspase 
activates a range of enzymes critical for inducing the structural rearrangement of 
the nucleus, cytoskeleton and plasma membrane that are characteristic of 
apoptosis.6 Apoptosis is defined as the transient opening of MPTP, as reclosure 
of the pore ensuring this transient process does not result in necrosis and ATP 
levels are ultimately maintained inside the cell.13 TSPO is an endogenous 
modulator of this process but the exact mechanism has not yet been definitively 
established. TSPO regulation may act at different levels and some proposed 
mechanisms include the modulation of the MPTP or the direct interaction with 
pro- or anti-apoptotic molecules.6 
In 2007 Li and co-workers17 showed that the specific TSPO ligand PK1119518 
induces mitochondrial release of cytochrome c and ultimately induced 
mitochondrial uncoupling. PK11195 also facilitates the induction of apoptosis, 
reverses Bcl-2-mediated inhibition of apoptosis, and facilitates TNF-R-induced 
necrosis, producing a multicomponent effect on the induction of cell death. 
Outline, it is important to note that the proapoptotic effects of PK11195 are 
significant only at concentrations 1000-fold higher that those required for 
specific binding to TSPO.13 
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TSPO and Immunomodulation 
The presence of TSPO in a wide range of immunomodulatory cells such as 
microglia, blood monocytes, lymphocytes, and leukocytes implies its involvement 
in immune response. The mechanism through which this occurs is largely 
unknown. Macrophages express high levels of TSPO binding sites and, in mouse 
studies, TSPO ligands, specifically benzodiazepines, inhibit the capacity of 
macrophages to produce ROS and inflammatory cytokines such as IL-1, TNFR, 
and IL-6. Furthermore, TSPO is involved in the regulation of phagocyte oxidative 
metabolism, a process that is normally required for inducing effective elimination 
of foreign antigens. This immunosuppressive function of some TSPO ligands 
suggests an important role in host defense mechanisms and inflammatory 
response. 
In the health CNS, TSPO is minimally expressed on microglial cells. Upon the 
injection of excitotoxic compounds, there occurs a dose-dependent increase in 
the level of TSPO, an up-regulation closely correlated with microglial activation. 
Inflammatory mechanisms initiated by microglia are implicated as part of the 
primary and secondary mechanisms of inflammatory neurodegenerative 
diseases, such as Alzheimer’s disease (AD),19 whereby the activation of microglia 
initiates an inflammatory response that may exacerbate neuronal damage. The 
inflammation that occurs in the brain during such neurodegenerative diseases is 
thought to involve TSPO through its increased presence in activated microglia, 
thus presenting the possibility for the use of specific TSPO ligands to prevent or 
limit neuroinflammation. However, the involvement of activated microglia in 
different CNS diseases differs with respect to its role in disease progression and 
severity. By use of TSPO as a marker for activated microglia, it is possible to 
determine exactly what role the neuroinflammation plays in specific CNS disease 
states, opening doors for treatment or inhibition of disease progression.13 
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The TSPO Altered Expression  
TSPO basal expression is up-regulated in a number of human pathologies, 
including a variety of tumors and neuropathologies, such as gliomas and 
neurodegenerative disorders (Huntington’s and Alzheimer’s diseases), as well as 
various forms of brain injury and inflammation.20,21,22 Furthermore, changes in 
TSPO receptor levels were found in anxiety and mood disorders.9,23,24 Recent 
evidences suggest that TSPO on glial cells may regulate the biosynthesis of 
neurosteroids, leading to the hypothesis of its potential role as key determinant 
for the treatment of neuropathological conditions.7,13 
 
TSPO in Cancer 
The recent literature on TSPO includes many reports dealing with TSPO and 
cancer. The rationale behind the potential application of TSPO-targeted 
therapies in cancer is based on two main features: i) alteration of TSPO 
expression in tumor cells and ii) TSPO-dependent apoptosis modulations. 
Considering TSPO expression, some of highest densities of TSPO are observed in 
neoplastic tissues and cell lines. Ovarian, hepatic and colon carcinomas, 
adenocarcinoma, and glioma all show increased TSPO densities relative to 
untransformed tissues. Even higher levels of TSPO density were observed in 
more rapidly proliferating breast cancer cells and more aggressive breast cancer 
phenotypes. In further, an important relationship between TSPO expression, 
proliferation rate and tumor aggressivity was recently documented by Hardwich 
and co-workers.25 These data suggest that monitoring TSPO expression may be 
relevant in the clinic and that the protein could be used as a diagnostic and/or 
prognostic marker. Some TSPO ligands may have potential as antitumor 
molecules which would be related to their antiproliferative and pro-apoptotic 
properties. Consistent with this, FGIN-1-2726 and PK1119518 were shown to have 
antitumoral activities and to induce apoptosis and cell cycle arrest in colorectal 
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and esophageal cancer cell lines, and cancer primary cell cultures. These 
observations indicate that TSPO is an attractive target in cancer therapy.6 
 
TSPO in Inflammation and Auto-Immune Diseases 
TSPO is also involved in the regulation of immune responses. In the immune 
system, TSPO is widely expressed: in the thymus, where the protein is restricted 
to the medulla, in the white pulp of the spleen, in the lymph nodes, in the Peyer 
patches of the intestine and in all human peripheral blood leukocyte subsets. As 
observed for tumoral cell lines, changes in TSPO expression have already been 
associated with several inflammatory conditions: PK11195 binding is up-
regulated in experimental autoimmune encephalitis, motor neuron axotomy, 
sciatic nerve degeneration and regeneration.27 TSPO ligands exhibit anti-
inflammatory properties. They modulate monocyte chemotaxis and humoral 
responses such as macrophage production of reactive oxygen intermediates, 
TNF, or IL-1 and IL-6.28 Both Ro5-4864 and PK11195 were show to limit the 
severity and progression of different inflammatory processes. For instance, they 
were highly potent at inhibiting inflammatory signs in two mouse models of 
acute inflammation, where a treatment with carrageenan induced a paw 
oedema formation and pleurisy.29 The potential therapeutic benefit of TSPO 
ligands is not restricted to arthritis treatment and may be enlarged to other 
auto-immune pathologies. The protective effect of Ro5-4864, PK11195 and 
SSR180575 was also demonstrated in a spontaneous inflammatory skin 
pathology developed in an in vivo model of lupus erythematosus.30 These 
examples support the rationale that targeting TSPO may have beneficial effect in 
the treatment of inflammatory disorders and auto-immune pathologies.6 
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TSPO in Viral Infection  
TSPO and TSPO ligands were shown to modulate responses to viral infection. 
Apoptosis blockade is a strategy adopted by the virus to circumvent the normal 
protective host response against viral infection. The interaction between ML11, a 
virulence factor produced by the Myxoma poxvirus, and TSPO resulted in the 
inhibition of the dissipation of the transmembrane mitochondrial potential and 
the blockade of the mitochondrial release of cytochrome c.31 This latter study 
was important as it demonstrated, for the first time, the direct interaction of 
TSPO with an anti-apoptotic protein. The demonstration that a pathogenic virus 
targets TSPO to inhibit apoptosis offers new prospects for the dissection of TSPO 
function but also for the definition of original anti-viral strategies.6 
 
 
TSPO in Neurodegenerative Diseases  
A dramatic increase in TSPO density has been observed following experimental 
injuries of the CNS and in pathological situations. In most lesions, the increase in 
TSPO density was associated with the inflammatory reaction of the nervous 
system. These conditions included inflammation,32 metabolic stress,33 traumatic, 
or ischemic chemically-induced brain injury in animal models.34 Similar changes 
in TSPO density are observed in acute and chronic neurodegenerative states in 
humans. For example, temporal cortex obtained from patients with Alzheimer’s 
disease show an increase in TSPO density. A highly significant increase in TSPO 
density was also observed in the putamen and a moderate but significant 
increase in the frontal cortex of patients suffering from Huntington’s disease.35 
Finally, Vowinckel and co-workers observed a correlation between [3H]PK11195 
binding and inflammation both in vitro and in vivo in multiple sclerosis and 
experimental autoimmune encephalomyelitis.36 Given these modulations, 
labelled PK11195 and positron emission tomography (PET) have been used for in 
vivo imaging of neuroinflammation in a variety of brain diseases and at different 
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disease stages to: i) detect in patients inflammatory changes and ii) monitor the 
progression of neuroinflammation as a marker of the disease activity. Consistent 
with these modulations and considering both the steroidogenic potential of TSPO 
ligands and the antiapoptotic property of the protein, it has been hypothesized 
that the modulation of TSPO functions could play neurotrophic and 
neuroprotective roles during neuronal damage. TSPO ligands might promote 
neuronal survival by acting at different levels, through the regulation of 
apoptosis which favoured the survival of glial cells and/or the production of 
mediators such as neurosteroids, cytokines or other neurotrophic factors that 
support nerve survival. For example in a same study the ligand SSR180575 and 
Ro5-4864 promoted neuronal survival and repair following axotomy.6,37 
 
TSPO in Anxiety  
In the brain, neurosteroids such as allopregnanolone and pregnenolone, acting 
as positive modulators of γ-aminobutyric type A (GABAA) receptors, exerting 
anxiolytic activity. 
Specific ligands targeting TSPO increase neurosteroid production and for this 
reason have been suggested to play an important role in anxiety modulation. 
Unlike benzodiazepines (Bzs), which represent the most common anti-anxiety 
drugs administered around the world, selective TSPO ligands have shown 
anxiolytic effects in animal models without any of the side effects associated 
with Bzs. Therefore, specific TSPO ligands that are able to promote 
neurosteroidogenesis may represent the future of therapeutic treatment of 
anxiety disorders. Furthermore, TSPO expression levels are altered in several 
different psychiatric disorders in which anxiety is the main symptom.9 
Anxiety is a normal reaction to stress, which helps people deal with daily 
difficulties and cope with them. When anxiety is excessive and disabling, it may 
become pathological and fall under the classification of an anxiety disorder 
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according to the diagnostic manual definition.38 Anxiety disorders are the most 
common and frequent mental disorders, affecting a significant percentage of the 
world's population (8-13%), and often overlapping with mood disorders and drug 
abuse.39 Anxiety disorders markedly affect the living conditions of patients and 
their relatives, jeopardizing work and family setting. In general, anxiety disorders 
are treated with medication, specific types of psychotherapy, or both. Treatment 
choices depend on the problem and the person’s preference. The diagnosis is 
difficult and complex because of the variety of possible causes and symptoms, 
often arising from highly personalized experiences. Anxiety disorders are 
classified as panic disorder (PD), obsessive-compulsive disorder (OCD), post-
traumatic stress disorder (PTSD), generalized anxiety disorder (GAD) and social 
and specific phobias. A combination of pharmacological and genetic 
manipulation studies has provided forceful evidences that the GABAergic system 
is strongly linked to the development of anxiety behaviours.  
The GABAA receptor is one of two ligand-gated ion channels responsible for 
mediating the effects of GABA, the major inhibitory neurotransmitter in the 
brain. In addition to the GABA binding site, the GABAA receptor complex appears 
to have distinct allosteric binding sites for benzodiazepines, barbiturates, 
ethanol, inhaled anaesthetics, furosemide, kavalactones, neuroactive steroids, 
and picrotoxin. The receptor is a multimeric transmembrane receptor consisting 
of five subunits (the most common type in the brain is a pentamer comprising 
two α, two β, and a γ subunit (α2β2γ)), arranged around a central pore.
40 Once 
bound by endogenous GABA, the protein receptor changes conformation within 
the membrane, opening the pore to allow chloride ions to pass down the 
electrochemical gradient. Activation of GABAA receptors tends to stabilize the 
resting potential. In that condition, the excitatory neurotransmitters cannot 
depolarize the neuron generating the action potential, so the net effect is 
typically inhibitory, reducing the activity of the neuron.  
The Bzs are a class of psychoactive drugs with anxiolytic, sedative, hypnotic, 
anticonvulsant, and muscle relaxant properties. Bzs bind at the interface of the 
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and  subunits on the GABAA receptor (BzR site). The long-term use of Bzs can 
cause physical dependence with risk of withdrawal symptoms and rebound 
syndrome. However, Bzs are the most commonly used medications to treat 
states of anxiety, and are ever prescribed for short term relief of severe anxiety 
disorders. Common medications are lorazepam, clonazepam, alprazolam, and 
diazepam. Once bound to the BzR, the Bz ligand locks the BzR into a 
conformation in which the GABA neurotransmitter has a much higher affinity for 
its receptor. This increases the frequency of opening of the associated chloride 
ion channel, thereby hyperpolarizing the membrane of the associated neuron.9 
Neurosteroids synthesised de novo in the brain modulate neuronal functioning 
and could play an important pathophysiological role. Interestingly, a variety of 
neurological and psychiatric disorders, such as anxiety, depression, and 
schizophrenia, have been associated with both abnormal levels of neurosteroids 
and perturbations of neurotransmission. Some of the endogenous neurosteroid 
GABAA modulators are allopregnanolone (3α,5α-tetrahydroprogesterone, ALLO), 
pregnenolone (PREG), and tetrahydrodeoxycorticosterone (THDOC). In addition, 
dehydroepiandrosterone sulphate (DHEAS), the most abundant steroid found in 
the body, exhibits a bimodal effect on GABAA receptors: it demonstrates positive 
allosteric modulation at low nanomolar concentrations, and negative allosteric 
modulation at high micromolar concentrations. The anxiolytic properties of 
DHEAS may also occur since it is metabolised to androsterone and 
androstanediol, which are positive modulators of the GABAA receptor. 
It has been recognized that neurosteroids are synthesized from cholesterol in the 
CNS by a cascade of enzymatic processes, controlled by both P450 and non-P450 
cytochrome enzymes.9,41 The first step in the neurosteroid synthesis is 
cholesterol conversion to pregnenolone, which occurs in mitochondria and is 
facilitated by TSPO. This step is the rate-limiting reaction of neurosteroid 
synthesis and appears to regulate the neurosteroid levels in the brain. The 
binding of TSPO ligands induces cholesterol transport and steroid formation, 
leading to the formation of active neurosteroids (ALLO), which positively 
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modulate the activity of the GABAA receptor, potentiating GABAergic 
transmission and thus explaining their anxiolytic activity, as primarily shown in 
animal models of anxiety,41 Figure 3. 
 
 
Figure 3. Role of TSPO ligands in neurosteroid-mediated allosteric modulation of the GABAA 
receptor (TSPO, Translocator Protein; P450ssc, Cholesterol side-chain cleavage cytochrome P-450 
complex; 3β-HSD, 3-hydroxysteroid dehydrogenase; 5-Red, 5-Reductase; 3-HSD, 3-
hydroxysteroid dehydrogenase; GABAA R, GABAA receptor). 
 
This evidence has suggested TSPO involvement in the secretion of neurosteroids, 
whose levels have been reported to be changed in several diseases and to be 
implicated in the pathogenic mechanisms of anxiety.9,42 Indeed, the important 
involvement of TSPO in anxiety in humans has been extensively demonstrated by 
numerous studies in which TSPO expression levels have been reported to be 
changed. Specifically, TSPO density is up-regulated in acute stress conditions and 
down-regulated in chronic or repeated stress. A decrease of TSPO density has 
been shown in blood cells (platelets or lymphocytes) of patients affected by 
different psychiatric disorders, mainly characterized by anxiety, such as 
generalized anxiety disorder, generalized social phobia, post-traumatic stress 
disorder, panic disorder, chronic obsessive–compulsive disorder and also in 
suicidal patients,43 as well as in healthy subjects with high trait anxiety levels. It 
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has been demonstrated that TSPO expression was significantly decreased in 
lymphocytes of patients with post-traumatic stress disorder,44 and in platelets of 
patients with panic disorder or major depressive disorder associated with severe 
separation anxiety symptoms.9 
 
TSPO Endogenous Ligands 
A wide variety of endogenous molecules with affinity for the TSPO and different 
chemical structures have been identified.  
Protoporphyrins (protoporphyrins IX, mesoporphyrins IX, deuteroporphyrins IX, 
hemin) exhibit a very high affinity for TSPO. As several steroidogenic tissues, such 
as the adrenal gland and testis, show high TSPO and porphyrin levels, it has been 
suggested a physiological role for the interaction of these two molecules. 
Furthermore, having a plane of symmetry (Figure 4), these molecules could bind 
dimerized form of TSPO, confirming in this way the postulated two-binding site 
model.2,13 
Protoporphyrin IX                                       Heme 
Figure 4. Chemical structures of protoporphyrin IX and heme 
Another endogenous ligand is cholesterol, as previously reported discussing the 
fundamental role of TSPO in the regulation of cholesterol transport and thus in 
the steroidogenesis. Again it has been shown that a dimeric form of TSPO 
possesses an enhanced binding capacity to cholesterol.2   
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In 1984 Corda et al. isolated and purified a neuropeptide able to inhibit diazepam 
binding to Bz binding site on brain membranes. This 11 kDa polypeptide, named 
DBI (diazepam binding inhibitor), is constituted by 86 amino acids and binds with 
low affinity both TSPO and CBR, while a short fragment of DBI, triakontatetra-
neuropeptide, is more selective for TSPO. Furthermore, DBI promotes loading of 
cholesterol to the cytochrome P-450scc and stimulates steroidogenesis by 
directly interacting with TSPO.2,45  
Finally, anthralin, a 16 kDa protein that has been demonstrated interact with 
both TSPO and dihydropyridine binding site, and phospholipase A2 have also 
been proposed as endogenous ligands for TSPO.2
 
TSPO Synthetic Ligands 
Synthetic TSPO selective ligands have been developed with the aim to deepen 
the knowledge of the exact pharmacological role of TSPO, to define its 
involvement in several patho-physiological conditions and to establish the 
structural requirements needed for an optimum of affinity.  
Initially, the most of these ligands have been designed starting from classical se-
lective CBR ligands, such as benzodiazepines, making the necessary structural 
modifies in order to shift the affinity toward TSPO. Until to date, the prototypic 
ligands, used as reference compounds in the development of TSPO 
pharmacophore models and in SAR studies, are the benzodiazepine Ro5-4864 
and the isoquinolinecarboxamide PK11195.13 
Subsequently, a number of diversified structures have been developed obtaining 
in some cases good results in term of affinity and selectivity, and leading to draw 
various TSPO pharmacophore models useful for designing novel synthetic 
derivatives. TSPO specific synthetic ligands do not have a typical shared structure 
and thus can be distinguished nine different classes of compounds (Figure 5)11: 
 Benzodiazepines (Diazepam, Ro5-4864) 
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 Isoquinoline and Quinazoline Carboxamides (PK11195) 
 Benzothiazepines (THIA-66, THIA-67, THIA-4i) 
 Benzoxazepines (Oxa-17f, Oxa-17j) 
 Imidazopyridines (Alpidem) 
 Phenoxyphenyl-Acetamide Derivatives (DAA1106) 
 Pyrazolopyrimidines (DPA-713) 
 Indolacetamide Derivatives (FGIN-1, SSR180575) 
 Indol-3-ylglyoxylamides (IND-18) 
 
 
Benzodiazepines 
The classical Bz, Diazepam, has long been used as an anxiolytic and also as an 
effective anticonvulsant. Its ability to enhance the affinity of GABA for its 
receptor by binding to the modulatory site has been well characterized. In 1977, 
Braestrup and Squires performed a study concerning the binding properties of 
[3H]Diazepam, identifying an alternative, saturable and specific binding site 
located on rat brain membranes and on mitochondrial fractions from rat kidney, 
liver and lung.1 Starting from this discovery, Bz-binding sites have been divided 
into central and peripheral types. Diazepam binds with nearly similar nanomolar 
affinity to both receptors, but other ligands show selectivity. Actually, the 
clinically inactive benzodiazepine Ro5-4864 (4'-clorodiazepam), showed high 
affinity for this peripheral site, now TSPO, and was unable to displace 
[3H]Diazepam from the central binding site. The main disadvantage of Ro5-4864 
is its species dependence, which implied markedly different results between rats 
and humans, partially limiting its usefulness as a tool to study TSPO.9 
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Isoquinoline and Quinazoline Carboxamides 
The Isoquinoline Carboxamide PK11195, was the first non-benzodiazepine type 
compound identified to bind the TSPO with high potency, and it is nowadays the 
most commonly used standard for this receptor.  
At the end of the nineties, it was (together with a number of structurally related 
analogues) widely used for studies aimed to define and map the binding site. 
Cappelli et al. presented a novel systematic approach to the study of the binding 
of PK11195-like compounds within TSPO site based on the design of 
conformationally constrained derivatives (II-IX, Figure 6) in which the orientation 
of the carbonyl dipole is suitably spaced around its degree of conformational 
freedom.46 Most of these derivatives showed TSPO affinities in the nanomolar 
range, Table 1. The carbonyl function was confirmed as the primary 
pharmacophoric element in the recognition at TSPO. Ligands with the greatest 
affinity (III-V, VII-IX) showed a restricted range of carbonyl orientations 
(comprised between 80° and 110°), suggesting the involvement of this moiety in 
a specific hydrogen-bonding interaction with suitable amino acids in the 
receptor. Quantitative structure-activity relationship (QSAR) studies evidenced 
that secondary amide derivatives showed significantly lowers TSPO affinity when 
compared with tertiary amides, and both benzyl and sec-butyl substituents 
raised as optimal groups for the interaction with the receptor. The pendant 
phenyl ring also held an essential pharmacophoric function. Finally the position 
and role of the nitrogen atoms in the quinoline and isoquinoline nuclei seemed 
to be irrelevant. 
Some years after, the same research group47 studied the radiolabelling of three 
quinoline derivatives (N-[11C]-III, N-[11C]-IV, N-[11C]-V) aiming to develop 
potential tools for the non-invasive assessment of TSPO in vivo by means of PET, 
in various pathological conditions including multiple sclerosis, human glioma, 
cerebral infarction and calcium channel anomalies in heart diseases. From these 
studies N-[11C]-V emerged of potential interest for in vivo imaging of TSPO, due 
to its high specific binding, as indicated by the high reduction of radioligand 
Introduction 
23 
 
uptake observed in the inhibition study with cold PK11195, and tissue-to-blood 
ratio. Evaluation of these ligands for in vivo measuring of TSPO expression in a 
preclinical model of Huntington’s disease, indicated that N-[11C]-V  is a promising 
candidate for in vivo PET monitoring of neurodegenerative processes. 
 
N
N
Cl
O
N
X
N
N
X
O
R2
PK11195 (I)
R1
CH3
B
N R1
O
(II) (III-V)
N
O
R1
R2
N
N
O
CH3
CH3
B
N
NB
O
R1
   (VI) (VII) (VIII,IX)
Figure 6. 
 
 
Table 1. Structures and TSPO Affinities of PK11195-Like Compounds II-IX. 
Compound Bridge(B) X R1 R2 IC50(nM)
a 
Ib - - - - 2.2 
II
b 
CH2 H CH(CH3)C2H5 - >10
4 
IIIb - H CH(CH3)C2H5 CH3 2.1 
IVb - F CH(CH3)C2H5 CH3 2.9 
Vb - H CH2C6H5 CH3 2.1 
VIb CH2 - CH(CH3)C2H5 - 620 
VII
b 
- - CH2C6H5 CH3 3.1 
VIIIb CH2CH2 - - - 8.9 
IXb OCH2CH2 - - - 10 
a
Affinities for [
3
H]PK11195 binding inhibition to rat cortex homogenates. 
b
Data taken from ref.46
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Encouraged by these results, further studies among the quinolinecarboxamide 
derivatives were performed with the aim to optimize the interaction with TSPO 
and once again develop candidates for PET studies.48 A novel series of quinoline 
compounds was synthesized to obtain a TSPO ligand liable to be labelled with 
different radionuclides and potentially useful in boron neutron capture therapy 
(BNCT).  
Among the newly synthesized compounds, the tertiary amides bearing a 
chloromethyl or 2-fluorophenyl group (XI-XIII) showed subnanomolar TSPO 
affinity and were found to be more potent than reference compound PK11195, 
thus representing interesting candidates for radiolabelling and PET studies, Table 
2. In addition, the powerful activity of compounds XI-XII in stimulating steroid 
biosynthesis demonstrated that these quinolinecarboxamide derivatives are able 
to reach and interact with TSPO in vivo and to stimulate the transport of 
cholesterol both in the brain and in peripheral tissue mitochondria. 
 
Table 2. Structures and TSPO Affinities of Compounds X-XIV. 
 
Y
N
R3
X
O
R1
R2
     (X-XIV)  
Compound X Y R1 R2 R3 IC50(nM)
a 
X H N CH2C6H5 CH3 CH3 4.6 
XI F N CH2C6H5 CH3 CH3 2.2 
XII H N CH2C6H5 CH2C6H5 CH3 11 
XIII H N CH2C6H5 CH3 CH2Cl 0.45 
XIV H N CH2C(B10H10)CH CH3 CH3 73 
aData taken from ref. 48 
 
As an extension of the SAR on TSPO ligands structurally related to PK11195, 
Anzini et al. performed the design of a series of carboxamide derivatives 
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endowed with differently substituted planar aromatic or heteroaromatic 
systems.49 The main aim was to get further information on the topological 
requisites of the carbonyl and aromatic moieties for interaction with  TSPO. New 
series of compounds were designed and tested (XV-XIX, Figure 7). Most of these 
derivatives showed TSPO affinity in the submicromolar range.  
 
N R N
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N CH3
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N
N
N
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O
N
R1 R2
(XVI)(XV) (XVII)
(XVIII) (XIX)
                                                                         IC50  4.1 nM          
Figure 7. Structures of carboxamide derivatives (XV-XIX). 
 
The integration of the information obtained allowed to draw the crucial 
structural requirements for binding with high affinity to TSPO: (i) the presence of 
a carbonyl dipole suitably located and oriented; (ii) lipophilic substituents 
attached to the 2-position; (iii) the presence of a bicyclic aromatic or 
heteroaromatic system bearing a suitably located pendant phenyl ring; in 
addition, a zone of tolerance for large substituents seems to be located in the 
TSPO site interacting with the 3-position of quinoline nucleus (Figure 8). The 
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most potent compound among the newly synthetized ones, XIX, showed a 
nanomolar TSPO affinity (IC50 4.1 nM) similar to that shown by PK11195. 
Furthermore, the presence of a basic N-ethyl-N-benzylaminoethyl group in 3-
position of the quinoline nucleus confers to XIX the possibility to make salts 
soluble in water. The high affinity of this compound suggested that the TSPO 
binding site seems to well tolerate the positive charge presumably borne by 
tertiary amine nitrogen at physiological pH. 
 
 
 
Figure 8. Schematic representation of the interaction of compound XIX with the TSPO binding 
site.49 
                                                                                        
With the aim to identify novel chemotype ligands for TSPO, a series of 
quinazolin-carboxamide derivatives was synthesized. Although structurally 
related to the isoquinolinecarboxamide PK11195, these quinazoline derivatives 
were assumed to have a better drug-like character, possessing a higher 
hydrophilicity and water solubility than their quite lipophilic isoquinoline 
counterpart. Indeed, preliminary calculations of several physicochemical and 
pharmacokinetic parameters conducted on the structures of PK11195 and of its 
aza-isoster supported our hypotheses. Taking into account the structural 
Short-range 
interactions 
Short-range 
interactions 
Zone of 
steric 
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H-bond interaction 
Short-range interactions 
N
N
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requirements needed for high TSPO affinity and selectivity,50 compounds 
featuring different combinations of R1−R5 substituents were designed. 
Specifically, symmetrically or asymmetrically N,N-disubstituted quinazolines 
bearing linear, branched, or alicyclic alkyl chains were synthesized. In addition, to 
investigate the role of a double substitution on the amide nitrogen to gain high 
TSPO affinity in this class, a number of N-monosubstituted derivatives were 
studied. Finally, a chlorine atom was inserted at different positions (2′, 4′, 6′) of 
the basic 4-phenylquinazoline scaffold. 
All novel compounds have been tested for their affinity at TSPO in rat kidney 
membranes, and SARs were razionalized in light of a previously published 
pharmacophore/topological model of ligand−TSPO interaction (Figure 9),51,52 
allowing to define the main structural requirements for an optimal interaction 
with the target protein, that is: (i) N,N-disubstitution on the carboxamide moiety, 
(ii) at least one of the two N-alkyl groups with a number of carbon atoms 
comprised between 4 and 6. The comparison of some calculated 
physicochemical and pharmacokinetic properties of PK11195 and of its aza-
isoster, evidenced a better drug-like character for quinazoline derivative. 
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Figure 9. General structure of quinazolinecarboxamide derivatives 
 
Benzothiazepines 
The Benzothiazepines ligands, including THIA-66 and THIA-67, (Figure 5) 
displayed nanomolar affinity and notable selectivity for TSPO binding sites; 
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however, they were less potent than PK11195. To date, THIA-4i has been 
reported as the most potent TSPO ligand from this class with an affinity 
comparable to that of the gold standard TSPO ligand PK11195. Although these 
ligands might be useful probes for in vitro studies, further evaluation is required 
to elucidate their in vivo pharmacological profile.11 
 
Benzoxazepines  
The Benzoxazepines (Figure 5) were synthesised based on a 
pyrrolobenzoxazepine skeleton. Ligands from this class were evaluated in binding 
studies for their ability to displace [3H]PK11195 from the receptor site. A number 
of these compounds displayed Ki values in the subnanomolar range. OXA-17f and 
OXA-17j were reported as the most potent TSPO ligands from this series with Ki 
values of 0.26 and 0.36 nM, respectively compared to Ki value of 0.78 nM for 
PK11195 in the same assay. All of these benzodiazepine-like compounds were 
shown to stimulate neurosteroids production with comparable potency to 
PK11195 and Ro5-4864 in mouse Y-1 adrenocortical cell line.11 
 
Imidazopyrdines and Phenoxyphenyl-Acetamides 
The progenitor of the class of Imidazopyridines has to be considered Alpidem (6-
chloro-2-(4-chloro-phenyl)-N,N-dipropylimidazo[1,2-a]pyridine-3-acetamide) 
(Figure 5), known to bind both TSPO and BzR with nanomolar affinity (Ki 0.5-7 
nM and 1-28 nM, respectively). Alpidem possesses anxiolytic activity with a 
profile that is substantially different from that of Bzs. Alpidem was released in 
1991 (Ananxyl®, Sanofi-Aventis) as a highly active anxiolytic agent and it was 
generally prescribed to patients with moderate to severe anxiety, particularly 
when these patients exhibited either sensitivity or resistance to Bz therapy. 
Alpidem was withdrawn from the market in most of the world, following reports 
of severe liver damage caused by Ananxyl.9 
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In 1997, Trapani’s research group reported a wide SAR study on alpidem, 
developing a series of 2-phenylimidazo[1,2-a]pyridine derivatives (CB) that 
showed various degrees of affinity and selectivity for TSPO with respect to BzR, 
dependent on the value of n and the nature of the various substituents R1, R2, X, 
Y, Z,53 Figure 10. 
N
N
CONR1R2
Z
Y
X
1
2
3
4
5
6
7
8
n
CB  
Figure 10. General formula of 2-phenylimidazo[1,2-a]pyridine derivatives CB. 
 
Three lead compounds selected from this series, N,N-di-n-propyl-[2-(4-
chlorophenyl)-6,8-dichloroimidazo[1,2-a]pyridin-3-ylacetamide CB34, N,N-di-n-
propyl-[2-phenyl-6,8-dichloroimidazo[1,2-a]pyridin-3-ylacetamide CB50, and 
N,N-di-n-propyl-[2-phenyl-6-bromo-8-methylimidazo[1,2-a]pyridin-3ylacetamide 
CB54 were investigated for their ability to stimulate central and peripheral 
steroidogenesis and to produce anticonflict action in rats,54 Figure 11. 
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Figure 11. Imidazopyridines tested in vivo as anxiolytics. 
 
In in vitro experiments performed on cerebral cortex membrane, all three 
compounds potently inhibited [3H]PK11195 binding in the order CB34 (IC50 1.03 
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nM) > CB54 (IC50 1.54 nM) > CB50 (IC50 3.04 nM), without substantially affecting 
[3H]flunitrazepam binding to BzRs. Intraperitoneal administration of CB 
compounds in rats resulted in significant dose-dependently increased 
concentrations of neuroactive steroids, such as pregnenolone, progesterone, 
allopregnanolone, and allotetrahydrodeoxycorticosterone (THDOC) in plasma 
and brain. CB34 also increased the brain concentration of neuroactive steroids in 
adrenalectomized-orchiectomized rats, although to a lesser extent than in sham-
operated animals. The effect of these ligands on neurosteroid concentration was 
attributable to increased steroidogenesis in the brain, rather than to an 
increased supply from peripheral sources. In this view, CB34 appeared to be a 
promising compound, which, acting as TSPO agonist, increased neuroactive 
steroid concentration, and proved beneficial for the treatment of stress and 
anxiety related diseases.9 
In 2004, the research group of Nakazato and colleagues from the Taisho 
Pharmaceutical and Co. described a novel class of selective TSPO ligands derived 
from a structural simplification of the bicyclic structure of the benzodiazepine 
Ro5-4864, which is the opening of the diazepine ring. The resulting 
Phenoxyphenyl-Acetamide derivatives with general formulae DAA, were 
synthesized and evaluated for their affinity and selectivity for TSPO in an 
extensive SAR study,55 Figure 12. 
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Figure 12. Design of DAA derivatives starting from Ro5-4864. 
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The Authors focused their attention on chemical modification of Ar1, Ar2, R1, X1, 
and Y, obtaining a number of compounds with remarkable affinity and 
selectivity, so that to define the most important structural features for this class 
of compounds in binding to TSPO.  
Two phenoxyphenylacetamide derivatives, N-(2,5-dimethoxybenzyl)-N-(5-fluoro-
2-phenoxyphenyl)acetamide (DAA1106) and N-(4-chloro-2-phenoxyphenyl)-N-(2-
isopropoxybenzyl)acetamide (DAA1097), Figure 13, have been extensively 
characterized with respect to their receptor binding and behavioural profile, as 
well as to their effect on steroidogenesis. 
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Figure 13. Structure of DAA1106 and DAA1097 derivatives. 
 
Both DAA1106 and DAA1097 inhibited [3H]PK11195 and [3H]Ro5-4864 binding to 
crude mitochondrial preparations of rat whole brain with IC50 values in the 
subnanomolar range (0.92 and 0.28 nM, and 0.64 and 0.21 nM, respectively).56 
These compounds were also highly selective, as they did not inhibit the binding 
of BzR ligand [3H]flunitrazepam (IC50 > 10,000 nM) in the same preparation, and 
showed weak or negligible affinity (IC50 values are approximately 10,000 nM) for 
58 other receptors, including those of related neurotransmitters, ion channels, 
uptake/transporter and second messengers. 
In a separate study the same research group performed an exhaustive 
characterization of the binding of DAA1106 in the mitochondrial fractions of rat 
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brain by means of its [3H]radiolabelled analogue. The binding of [3H]DAA1106 
was saturable, with a dissociation constant (Kd) determined from a Scatchard 
plot analysis of 1.2 nM. The binding was inhibited by several TSPO ligands in an 
order similar to that observed for [3H]PK11195, with DAA1106 being the most 
potent inhibitor. In addition, [3H]DAA1106 was highly TSPO selective, as its 
binding was not affected by several neurotransmitter-related compounds, 
including adrenoceptor, GABA, dopamine, 5-hydroxytriptamine (5-HT), 
acetylcholine, histamine, glutamate and BzR ligands even at a concentration of 
10 μM. When tested on mitochondrial fractions of the rhesus monkey cerebral 
cortex, [3H]DAA1106 showed a high affinity for TSPO (Kd 0.426 nM), with its 
binding being potently inhibited by DAA1106 and PK11195, but not by Ro5-4864, 
even at 1 μM. The results indicated that this ligand was not species dependent, 
similar to PK11195 and contrary to Ro5-4864. Autoradiography and biochemical 
studies on rat brain showed that the highest binding of [3H]DAA1106 is localized 
in the olfactory bulb and ventricular structures related to the secretion of 
cerebrospinal fluid (choroid plexus), followed by the cerebellum and cerebral 
cortex.9 In in vivo studies, DAA1106 and DAA1097 showed potent anxiolytic-like 
properties in laboratory animals, in both the light/dark exploration test in mice 
and the elevated plus-maze test in rats.54 
Even though these two phenoxyphenylacetamides have a similar structure, 
potently bind to TSPO and exert anxiolytic effects, their effects on 
steroidogenesis appeared to be opposite. Culty and colleagues 57 examined the 
effects of these two ligands on steroidogenic response using MA-10 Leydig tumor 
cells, C6-2B glioma cells, and rat brain mitochondria. It has been observed that 
DAA1097 activated steroidogenesis in all the three preparations in a similar 
fashion to that described for PK11195, and more efficiently on brain than Leydig 
cells. Surprisingly, DAA1106 did not activate steroidogenesis, despite its high 
affinity for TSPO. 
It has been suggested that the DAA1097 and DAA1106 binding sites on TSPO 
share a common domain with that of PK11195, but also appear to contain 
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additional motif(s) that do not interact efficiently with PK11195 site. The 
different effect on steroidogenesis has been rationalized by hypothesizing that 
the binding of DAA1097 induce changes in the receptor similar to that triggered 
by PK11195, allowing steroidogenesis activation. On the contrary, the binding of 
DAA1097 leads to conformational changes that do not permit or antagonize 
TSPO steroidogenic function.9, 55 
 
Pyrazolopyrimidines 
The Pyrazolopyrimidines (Figure 5) are bioisteres of the imidazopyridine 
derivatives and hence are structurally related to alpidem. Binding assays, using 
[3H]PK11195 as the radioligand and membranes from rat kidney tissue as 
receptor source, showed that a subset of ligands from this pyrazolopyrimidine 
series displayed high binding affinity (Ki) for the TSPO ranging from 0.8-6.1 nM. 
Some of these compounds were shown to stimulate steroid biosynthesis in C6 
glioma rat cells with a few capable of increasing pregnenolone synthesis with 
similar potency to Ro5-4864 and PK11195.58 
 
Indoleacetamide Derivatives 
The Indoleacetamide derivatives were found to enhance steroidogenesis and to 
be highly selective for the TSPO. The lead compound from this class is known as 
N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide (FGIN-1-27,26 Figure 5). 
FGIN-1-27 has a high affinity (Ki 5.0 nM, displacement study using [
3H]PK11195) 
and is able to penetrate the blood brain barrier. FGIN-1-27 has also been shown 
to induce sedation and ataxia at micromolar intravenous doses. It was 
hypothesised that the pharmacological actions of this compound are most likely 
due to its indirect action on GABAA receptors via the stimulation of neurosteroid 
production.11 
SAR studies allowed the authors to identify the structural features of FGIN-1 
derivatives essential for high affinity: (i) the presence of two alkyl groups on the 
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amide nitrogen; (ii) the length of such alkyl chains, with the N,N-di-n-hexyl 
groups conferring an optimum of affinity, twenty fold higher than the 
corresponding N,N-dimethyl analogues; (iii) halogenation of the pendant 2-aryl 
groups and the indole benzofused ring (X and R3 = Cl, F). Broad screening studies 
revealed that these FGIN-1 derivatives were highly TSPO selective, as they failed 
to bind with any significant affinity (Ki > 1000 nM) to other receptor systems, 
including the GABAA, GABAB, glycine, glutamate, dopamine, serotonin, opiate, 
cholecystokinin, beta adrenergic, cannabinoid, and sigma receptors. Compounds 
exhibiting the highest TSPO binding affinity were selected to evaluate their ability 
to stimulate pregnenolone formation from the mitochondria of C6-2B glioma 
cells.9 
Another high affinity TSPO ligand structurally related to this class of compounds, 
7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5 b]indole-
1-acetamide (SSR180575, Figure 5), has been shown to promote neuronal 
survival and repair. SSR180575 displays nanomolar affinity, four times greater 
than that of Ro5-4864, for both the rat and human TSPO. Moreover, SSR180575 
increased pregnenolone accumulation in the brain implying that the therapeutic 
effects may be mediated through its ability to stimulate steroidogenesis.11 
 
N,N-dialkyl-2-phenylindol-3-ylglyoxylamides 
In the last decade, a novel series of highly potent and selective TSPO ligands, 
which represent conformationally constrained analogues of FGIN-1 derivatives, 
was developed and they are known as the N,N-dialkyl-2-phenylindol-3-
ylglyoxylamides (XX, Figure 14).9,59 Within this class, SAR studies were 
rationalized in light of the recently reported pharmacophore/receptor model 
made up of three lipophilic pockets (L1, L3, and L4) and an H-bond (H1) donor 
group, Figure 14. 
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Figure 14. PK11195 and N,N-dialkyl-2-phenylindolylglyoxylamides in the 
pharmacophore/receptor model of TSPO. 
 
The SAR data deriving from the biological results of the newly synthesized N,N-
dialkyl-2-phenylindol-3-ylglyoxylamide TSPO ligands led to a refinement of TSPO 
pharmacophore/topological model: (i) the R3 substituent has to be electron-
withdrawing to reinforce a putative π-stacking interaction between the 2-phenyl 
and an electron-rich aromatic ring within the L1 pocket; (ii) R4 has to be both 
electronwithdrawing and very small for optimal binding, a combination of 
properties featured only by fluorine; (iii) substitutions in the 7-position of the 
indole nucleus (R5) do not produce any gain in affinity; (iv) an aromatic moiety 
(R1/R2) is equivalent to an aliphatic moiety of similar size in interacting 
hydrophobically with the L3 or L4 lipophilic pocket; (v) the L3 and L4 pockets are 
probably different in their dimensions, as the best-performing substitution 
pattern on the amide nitrogen is obtained with R1 and R2 of different sizes.  
Most of the new compounds exhibited a high affinity for TSPO, with Ki values in 
the nanomolar/subnanomolar range, and stimulated steroid biosynthesis in rat 
C6 glioma cells to an extent similar to or higher than that of classic TSPO ligands 
such as PK11195, Ro5-4864, and alpidem. Furthermore, in the EPM test, the 
indole derivative  featuring R1=CH2CH3, R2=CH2C6H5, R3=R4=Cl, and R5=H, elicited 
an anxiolytic activity.  
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Taken together, the results of the present study suggest that the novel N,N-
dialkyl-2-phenylindol-3-ylglyoxylamides may represent promising 
pharmacological tools suited for the treatment of anxiety disorders. 
 
 
Molecular Probes for the receptor characterization 
using Chemical and Physical Techniques: Radioligands 
and Fluorescent Ligands 
Molecular Imaging is a new discipline that unites molecular biology and in vivo 
imaging. It enables the visualization of the cellular function and the follow-up of 
molecular processes in living organisms without perturbing them. The multiple 
and numerous potentialities of this field are applicable to the diagnosis of 
diseases such as cancer, and neurological and cardiovascular diseases. This 
technique also contributes to improve the treatment of these disorders by 
optimizing the pre-clinical and clinical tests of new medications. It is also 
expected to have a major economic impact due to earlier and more precise 
diagnosis. Molecular and Functional Imaging has taken on a new direction since 
the description of the human genome.  
Molecular imaging differs from traditional imaging in that probes known as 
biomarkers are used to help to image particular targets or pathways. Biomarkers 
interact chemically with their surroundings and in turn alter the image according 
to molecular changes occurring within the area of interest. This process is 
markedly different from previous methods of imaging which primarily imaged 
differences in qualities such as density or water content. The ability to image fine 
molecular changes opens up an incredible number of exciting possibilities for 
medical application, including early detection and treatment of disease and basic 
pharmaceutical development. Furthermore, molecular imaging allows 
quantitative tests, imparting a greater degree of objectivity to the study of these 
areas.  
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Many areas of research are being conducted in the field of molecular imaging. 
Much research is currently centered on detecting what is known as a predisease 
state or molecular states that occur before typical symptoms of a disease. Other 
important veins of research are the imaging of gene expression and the 
development of novel biomarkers.  
There are many different modalities that can be used for noninvasive molecular 
imaging: Magnetic Resonance Imaging (MRI), Optical Imaging (Fluorescent 
probes and labels are an important tool for optical imaging.), Single photon 
emission computed tomography (SPECT), Positron Emission Tomography (PET). 
The founding principles of molecular imaging can be traced back to nuclear 
medicine procedures over the past few decades, with other technologies (e.g., 
optical, MRI) being adapted for molecular imaging by developing different types 
of molecular probes. At the widest level, there exist two classes of probes: 
nonspecific and specific. Nuclear medicine plays a key role in the latter class, as 
the signaling portion of specifically targeted probes. Probes that use antibodies, 
ligands, or substrates to specifically interact with protein targets in particular 
cells or subcellular compartments include those used in most of the conventional 
radiotracer imaging methods, where the emphasis is on imaging final products of 
gene expression with radiolabelled substrates that interact with a protein 
originating from a specific gene. These interactions are based on either receptor-
radioligand binding (e.g. binding of 11C-carfentanil to the mu opiate receptor) or 
enzyme mediated trapping of a radiolabelled substrate (e.g. 18F-2-fluoro-2-
deoxyglucose [18F-FDG] phosphorylation by hexokinase). 
However, the main limitation of most of these specific approaches is that a new 
substrate must be discovered and radiolabelled to yield a different probe for 
each new protein target. With the significant difficulty, cost, and effort involved 
in radiolabeling new substrates, along with the requirement for in vivo 
characterization of every substrate under investigation, more generalizable 
methods (i.e. those that can image gene product targets arising from the 
expression of any gene of interest) are preferred. In recent years, this issue has 
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propelled the development and validation of molecular imaging reporter 
gene/reporter probe systems for use in living subjects together with other 
generalizable strategies. 
The various existing imaging technologies differ in five main aspects: (i) spatial 
resolution; (ii) depth penetration; (iii) energy expended for image generation 
(ionizing or no ionizing, depending on which component of the electromagnetic 
radiation spectrum is exploited for image generation); (iv) availability of 
injectable/biocompatible molecular probes; and (v) the respective detection 
threshold of probes for a given technology, Table 3. 
Molecular imaging has revolutionized the practice of medicine and is critical to 
quality health care. Molecular imaging delivers on the promise of "personalized 
medicine"; it can provide patient-specific information that allows treatment to 
be tailored to the specific biological attributes of both the disease and the 
patient.  
With molecular imaging, abnormalities may be detected very early in the 
progression of a disease, often before medical problems can be detected by 
other diagnostic tests and even before symptoms occur. Such early detection 
allows a disease to be treated early when there may be a more successful 
outcome. 
A molecular imaging probe is a molecule used in molecular imaging to deliver a 
tracer to a specific organ or tissue. Some examples of molecular probes are 
Radioligands and Fluorescent ligands. 
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Table 3. Key advantages and disadvantages of the main available imaging 
modalities used in molecular approaches. 
Imaging Technique  EM Radiation 
Spectrum Used In 
Image Generation  
Advantages Disadvantages 
Positron emission 
tomography (PET)  
High energy gamma 
rays  
- high sensitivity; isotopes 
can substitute naturally 
occurring atoms; 
- quantitative; 
- translational research 
- PET cyclotron or generator 
needed; 
- relatively low spatial 
resolution;  
- radiation of subject 
Single photon 
emission computed 
tomography (SPECT)  
Lower energy 
gamma rays  
- availability of many 
molecular probes;  
- possibility to image 
multiple probes 
simultaneously; 
- possibility to be adapted to 
clinical imaging systems 
- relatively low spatial 
resolution; 
- radiation 
Optical 
bioluminescence 
imaging  
Visible light  - highest sensitivity; 
- quickness and easiness: 
- low cost, and relatively 
high throughput 
- low spatial resolution; 
- current 2-D imaging only; 
- relatively surface-
weighted; 
- limited translational 
research 
Optical fluorescence 
imaging  
Visible light or near-
infrared  
- high sensitivity;  
- detection of fluorochrome 
in live and dead cells 
- relatively low spatial 
resolution; relatively 
surface-weighted 
Magnetic resonance 
imaging (MRI)  
Radio waves  - highest spatial resolution;  
- combines morphologic and 
functional imaging 
- relatively low sensitivity;  
- long scan and 
postprocessing time;  
- mass quantity of probe 
may be needed 
Computed 
tomography (CT)  
X-rays  - bone and tumor imaging;  
- anatomic imaging 
- limited 'molecular' 
applications;  
- limited soft tissue 
resolution;  
- radiation 
Ultrasound  High-frequency 
sound  
- real time;  
- low cost 
- limited spatial resolution;  
- mostly morphologic 
although targeted 
microbubbles under 
development 
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PET and Radioligands  
Positron emission tomography (PET) is a nuclear medicine imaging technique 
which produces a three-dimensional image or picture of functional processes in 
the body. PET uses radiopharmaceuticals that emit positrons (positively charged 
electrons). A radiopharmaceutical such as FDG (Fludeoxyglucose (18F)), an 
analogue of glucose, is injected into the patient, the concentration of the tracer 
imaged then gives tissue metabolic activity in terms of regional glucose uptake. 
The fluorine emits positrons which react with the first electron they come in 
contact with, annihilating both and producing energy according to Einstein's 
famous E=MC2 formula. This energy takes the form of two photons (particles of 
light) with a very specific energy level that shoot off in opposite directions. When 
these photon pairs are detected by the PET scanner, the location of the original 
fluorine atom can be extrapolated. Although positron/electron annihilation is 
one of the most powerful reactions known to science, the amount of mass 
involved is so small that the actual energy produced is not harmful to the 
patient, and the fluorine decays rapidly into harmless oxygen. 
A PET scanner consists of a circular array of detectors tuned to detect photons at 
the specific energy level created by the positron/electron annihilation (Figure 
15). Topographic reconstruction software assembles these signals into images 
that show the location and concentration of the radiopharmaceutical inside the 
patient. When scanning with FDG, the rapidly dividing cancer cells use a lot of 
glucose to fuel their growth; therefore, they show up as "hot spots" on the PET 
image. 
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Figure 15. 
 
PET scanning uses radionuclides, that are typically isotopes with short half lives 
such as carbon-11 (20 min), nitrogen-13 (10 min), oxygen-15 (2 min), and 
fluorine-18 (110 min). These radionuclides are incorporated either into 
compounds normally used by the body such as glucose (or glucose analogues), 
water or ammonia, or into molecules that bind to receptors or other sites of drug 
action. Such labeled compounds are known as radioligands. 
It is important to recognize that PET technology can be used to trace the biologic 
pathway of any compound in living humans (and many other species as well), 
provided it can be radiolabelled with a PET isotope. Due to the short half lives of 
most radioisotopes, the radioligands must be produced using a cyclotron and 
radiochemistry laboratory that are in close proximity to the PET imaging facility. 
The half life of fluorine-18 is long enough such that fluorine-18 labeled 
radiotracers can be manufactured commercially at an offsite location. There is no 
chemical difference between the way the radioactive and non-radioactive 
versions of an element react. The fact that there is no difference allows the 
radioactive versions of the element to be substituted for the non-radioactive 
versions to produce a tracer.  
PET is useful in diagnosing certain cardiovascular and neurological diseases as it 
highlights areas of increased, diminished, or absent metabolic activity. PET is 
mainly used in determining the presence and severity of cancers, neurological 
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conditions, and cardiovascular diseases. It is also used to identify and stage 
cancers in the initial diagnosis and to check for recurrences. An example of how 
PET can be uniquely useful is in following patients after radiation therapy. The 
radiation may create scar tissue at the cancer site. Other medical imaging 
techniques can only identify the scar tissue as a "mass," i.e. it looks the same 
before and after therapy, while PET can indicate whether or not the mass is still 
malignant. 
PET scanning with the tracer fluorine-18 (F-18) fluorodeoxyglucose (FDG), called 
FDG-PET, is widely used in clinical oncology. FDG-PET can be used for diagnosis, 
staging, and monitoring treatment of cancers, particularly in Hodgkin's disease, 
non Hodgkin's lymphoma, and lung cancer. Many other types of solid tumors will 
be found to be very highly labeled on a case-by-case basis, a fact which becomes 
especially useful in searching for tumor metastasis, or for recurrence after a 
known highly active primary tumor is removed. 
PET neuroimaging is based on an assumption that areas of high radioactivity are 
associated with brain activity. What is actually measured indirectly is the flow of 
blood to different parts of the brain, which is generally believed to be correlated 
with brain activity, and has been measured using the tracer oxygen-15. However, 
because of its 2-minute half-life O-15 must be piped directly from a medical 
cyclotron for such uses, and this is difficult. In practice, as the brain is normally a 
rapid user of glucose, and since brain pathologies such as Alzheimer's disease 
greatly decrease brain metabolism of both glucose and oxygen in tandem, 
standard FDG-PET of the brain, which measures regional glucose use, may also 
be successfully used to differentiate Alzheimer's disease from other dementing 
processes, and also to make early diagnosis of Alzheimer's disease. The main 
advantage of FDG-PET for these uses is its much wider availability. Several 
radiotracers C-11 or F-18 (i.e. radioligands) have been developed that are ligands 
for specific neuroreceptor subtypes of interest in biological psychiatry such as 
[11C]-raclopride and [18F]-fallypride for dopamine D2/D3 receptors, [
11C]McN 5652 
and [11C]DASB for serotonin transporters, or the visualization of neuroreceptor 
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pools in the context of a plurality of neuropsychiatric and neurologic illnesses. In 
addition, studies have been performed examining the state of these receptors in 
patients compared to healthy controls in schizophrenia, substance abuse, mood 
disorders and other psychiatric conditions. 
PET is used also in pharmacology. In pre-clinical trials it is possible to radiolabel a 
new drug and inject it into animals. These scans are referred to as biodistribution 
studies. The uptake of the drug, the tissues in which it concentrates, and its 
eventual elimination, can be monitored more quickly with respect to the older 
technique of killing and dissecting the animals to discover the same information. 
Much more commonly, however, drug occupancy at a purported site of action 
can be inferred indirectly by competition studies between unlabeled drug and 
radiolabelled compounds known a priori to bind with specificity to the site. A 
single radioligand can be used to test many potential drug candidates for the 
same target. A related technique involves scanning with radioligands that 
compete with an endogenous (naturally occurring) substance at a given receptor 
to demonstrate that a drug causes the release of the natural substance. 
PET imaging using specific TSPO ligands to label activated microglia may help to 
track the progression of neuroinflammation and may also aid in determining the 
effectiveness of therapies designed to treat neuroinflammatory diseases.60 The 
density of TSPO is greatly increased in disease states, reflecting the inflammatory 
reaction to brain injury; in this vein, TSPO ligands can be used as markers of 
microglia activation, neuroinflammation, and neuronal damage. Radiolabelled 
[3H]PK11195 and other TSPO ligands have been used to image 
neurodegenerative pathologies such as Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD), and Multiple Sclerosis (MS). PET imaging 
using TSPO ligands to label activated microglia and therefore neuronal cell loss 
can help to understand the regional brain distribution and severity of 
neuroinflammation and can be a valuable tool to determine different approaches 
to take in the treatment of each individual disease.13 
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In 1998, novel phenoxyphenyl acetamide derivatives were developed showing 
potent and selective binding affinities for TSPO. Among these compounds, two 
promising ligands, DAA1106 and DAA1197, were labeled with 11C and evaluated 
as PET ligands for TSPO with mice, rats, and monkeys. These [11C]ligands pass 
across the blood–brain barrier and the rat brain. Ex vivo autoradiography 
showed that the [11C]ligands preferably distributed in the olfactory bulb and 
cerebellum, two regions with richer TSPO density in the rat brain. PET study 
determined that the [11C]ligands preferably accumulate in the occipital cortex of 
the monkey brain, a region with a high density of TSPO in the primate brain.61 
Activation of microglia cells plays an important role in neurological diseases. PET 
with [11C]-(R)-PK11195 has already been used to visualize activated microglia 
cells in neurological diseases. However, [11C]-(R)-PK11195 may not possess the 
required sensitivity to visualize mild neuroinflammation. 
In 2009 a study of Doorduin62 evaluated the PET tracers [11C]-DPA-713 and [18F]-
DPA-714 as agents for imaging of activated microglia in a rat model of herpes 
encephalitis. Uptake of [11C]-DPA-713 in infected brain areas was comparable to 
that of [11C]-(R)-PK11195, but [11C]-DPA-713 showed lower non-specific binding. 
Non-specific uptake of [18F]-DPA-714 was lower than that of [11C]-(R)-PK11195. In 
the infected brain, total [18F]-DPA-714 uptake was lower than that of [11C]-(R)-
PK1195, with comparable specific uptake. [11C]-DPA-713 may be more suitable 
for visualizing mild inflammation than [11C]-(R)-PK11195. In addition, the fact 
that [18F]-DPA-714 is an agonist PET tracer opens new possibilities to evaluate 
different aspects of neuroinflammation. Therefore, both tracers warrant further 
investigation in animal models and in a clinical setting. 
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Positron Emission Tomography (PET) enables evaluation of target protein 
expression by measuring the radioactivity of a ligand labelled with a positron-
emitting radionuclide. PET studies of TSPO could offer quantitative follow-up of 
neuroinflammation, an advantage for biomarker-type measurement during drug 
development and early clinical development.63 
[11C]PK1119564,65 was the first tracer to be consistently used in PET imaging 
studies of neuroinflammation, although numerous limitations have been pointed 
out, including a high level of non-specific binding, and a poor signal-to-noise 
ratios which complicate its quantification.66 Subsequently, many groups 
worldwide were actively engaged in a search for TSPO ligands with improved 
capacities to quantify TSPO expression. Chaveau et al.63 have recently reviewed 
the main TSPO ligands that have been radiolabelled, evaluated in imaging 
protocols, and proposed as challengers of [11C]PK11195. 
 
 
 
The first aim of this thesis work it has been the preparation of the appropriate 
precursor to obtain [18F](R)-PK14105, a [18F]-labelled isoquinoline derivative 
analogue of  PK11195.  
The isoquinolinecarboxamide PK14105, [N-methyl-N-(1-methyl-propyl)-1(2-
fluoro-5-nitrophenyl)isoquinoline-3-carboxamide] 6 (Figure 16), has been 
previously labelled with fluorine-18 (t1/2 – 109.7 min)
69 and evaluated in rat as a 
prospective radiotracer for imaging human TSPO 18 kDa with PET. This 
radiotracer initially appeared promising, but extensive evaluation was hindered 
by its rather difficult radiosynthesis based on substitution of a chloro-substituent 
with cyclotron–produced [18F]fluoride ion (Figure 16). 
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Figure 16. The synthesis of [18F]PK 14105 
 
Recently, it has been shown that simple p-nitroarylsulfoxides react readily with 
[18F]fluoride ion to produce the corresponding [18F]p-nitrofluoroarenes in good 
radiochemical yields.70 This method might be applied to enhance the 
radiosynthesis of [18F]PK14105 as its higher affinity single R-enantiomer, and so 
permit detailed evaluation of its radiotracer properties in monkey with PET. In 
this view, the synthesis of the sulfoxide precursor of [18F]PK14105 was 
performed following the general synthetic route described in Scheme 1.  
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To a solution of methyl 1,2-dihydro-1-oxoisoquinoline-3-carboxylate 1 in dry 
acetonitrile, oxophosphobromide was added and the solution was heated to 
reflux for 90 minutes. The product was utilized in the following reaction without 
any further purification. The bromoisoquinoline ester 2 obtained was then easily 
hydrolyzed into the corresponding acid 3 by treatment with LiOH. To a solution 
of compound 3 and 1-hydroxybenzotriazole hydrate (HOBt) mixed in dry CH2Cl2, 
under nitrogen, (R)-sec-butylamine and N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide (EDC) were added and the reaction mixture was stirred at 
room temperature overnight. The product 4 was purified by flash 
chromatography (hexane:AcOEt=5:5 as eluent). Then compound 4 was 
methylated by treatment with sodium hydride and subsequent addition of an 
excess of methyl iodide to yield 5, that was purified by flash chromatography 
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(hexane:AcOEt=5:5 as eluent). PK14105 (6) was synthesized starting from 
compound 5 which reacted with 2-fluoro-5-nitrophenylboronic acid using 1,1’-
Bis(diphenylphosphino)ferrocene as catalyst and aqueous K2CO3 as base. The 
reaction mixture was stirred at 85 °C overnight. Product 6 was purified by flash 
chromatography (hexane:AcOEt=5:5 as eluent). In the next step compound 6 was 
dissolved in absolute ethanol and then thiophenol was added following by a 
solution of KOH. The reaction was mantained under stirring at room temperature 
until the disappearance of the starting material (TLC analysis). The sulfide 7 was 
then oxidated by treatment with meta-chloroperbenzoic acid to give the target 
sulfoxide 8 in 55% yield. The final product was purified by flash chromatography 
(hexane:AcOEt=4:6 as eluent).  
 
 
 
The second aim of this thesis work has been to apply the same strategy to obtain 
a 18-F labelled derivatives featuring the quinazoline scaffold (Figura 17). Actually, 
quinazoline derivatives are assumed to have a better drug-like character with 
respect to the quinoline compounds, because of their higher hydrophilicity and 
water solubility.  
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Figure 17. The planned synthesis of [
18
F]-labelled quinazoline derivatives. 
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In this view, we planned to synthesize compound 16, the aza-isoster of 
compound 8, following a synthetic procedure similar to that followed to obtain 8, 
and outlined in Scheme 2. 
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Bromination of ethyl 3,4-dihydro-4-oxoquinazoline-2-carboxylate 9 with 
phosphorus tribromide gave the bromoquinazoline ethyl ester 10, that was 
obtained in a very low yield, about 10-12 %, because of the instability of the 
product. This compound was purified by flash chromatography 
(hexane:AcOEt=5:5 as eluent). Coupling of 10 with 2-fluoro-5-nitrophenyl 
boronic acid gave compound 11 in 50% yield (purification by flash 
chromatography: (hexane:AcOEt=6:4 as eluent). The ethyl ester moiety was 
easily hydrolyzed into the corresponding acid 12 and then transformed into 
compound 13 by reaction with SOCl2, and subsequent addition of (R)-sec-
butylamine. Also compound 13 must necessarily purified by flash 
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chromatography (hexane:AcOEt=6:4 as eluent) and was obtained in a very low 
yield (about 5%). 
Because of these problems it has been tried an alternative way to prepare 
compound 16, outlined in Scheme 3. Compound 11, obtained as previously 
described, was reacted with tiophenol at room temperature overnight. 
Unfortunately, neither of the two products obtained and purified by flash 
chromatography, was the desired compound.  
 
 
Scheme 3. 
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We are currently evaluating alternative synthetic protocols that allowed us to 
obtain the desired products with acceptable yields. As an example, a possible 
way to synthesize compound 16 is outlined in Scheme 4. Because of the well-
known high reactivity of fluorobenzene,71 increased also by the presence of an 
electron-withdrawing nitro group at the para position,72 it should be better to 
react the fluoro compound with tiophenol as first step. The obtained phenyl 
boronic acid 19, might be then coupled with the bromo-derivative 10, in order to 
obtain compound 20. At this point, it should be easier to prepare the amide 
derivative by treatment with (R)-sec-butylamine and also  the other steps should 
work, too. 
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Scheme 4. 
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Radiochemistry 
Within a collaboration between the research group of Prof. Federico Da Settimo 
and Dr. Victor W. Pike, Senior Investigator of Molecular Imaging Branch (MIB) of 
the National Institute of Health (NIH), product 8 was submitted to radiolabelling 
reaction to obtain the desired [18F]PK14105. The potential advantages of 
microreactor technology for PET radiochemistry are increasingly recognized.67,68 
In this study, all radiofluorination reactions were performed in a commercially 
available microreactor apparatus (Nanotek; Advion). The use of this apparatus 
offers several advantages over traditional methods of studying radiofluorination 
reactions, which are usually performed singly with substantial amounts of 
nonradioactive precursor (e.g., milligram quantities of precursor for labeling). By 
use of the microreactor apparatus, a series of reactions can be performed rapidly 
with very low fixed quantities of reagents, under precisely controlled conditions 
of temperature, time, and reaction stoichiometry. The whole microreactor is 
heated to a controlled temperature, which can be well above the boiling point of 
most organic solvents due to the elevated pressure of the system. Figure 18. 
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Figure 18. Reactions of Sulphoxide with [18F]Fluoride Ion 
 
NCA (no-carrier-added) [18F]-fluoride ion acqueous solution (250 ml, from a 
mixture of 400 ml target water and 100 ml stock solution of 0.5 mg K2CO3 and 5.0 
mg K 2.2.2 in 9:1 MeCN and H2O mixture) was transferred to a glass V-vial (5 ml) 
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that had been loaded with MeCN (600 ml), and placed in a heating well inside a 
lead-shielded hot-cell. Water was removed by azeotropical distillation with 
acetonitrile under N2 gas flow (200 ml/min) at 110 °C. The addition of MeCN (650 
ml) and heating cycle were repeated three more times. The anhydrous NCA [18F]-
fluoride ion-K+ -K 2.2.2 reagent was redissolved in DMF (450 ml). This solution 
was then loaded into storage loop 3 of the microfluidic apparatus. A solution of 
precursor in anhydrous DMF (10 mM, 275 ml) was loaded into storage loop 1. A 
quantity of each solution (20 ml) was infused simultaneously at 4 or 2 ml/min 
into the 4 m-length coiled silica glass tube micro-reactor (31.4 ml) held at a set 
temperature. The affluent from the micro-reactor was quenched with H2O-MeCN 
(1:1 v/v, 0.5 mL) and analyzed with radio-HPLC. 
 
Table 4. Radiosynthesis of [18F]PK14105 in micro-reactor 
Run Temp (°C) Flow rate 
(ml/min) 
Recovery 
(%) 
RCY (%) 
By HPLC peak 
1 100 4+4 21 11.4 
2 130 4+4 37 46.1 
3 160 4+4 51 56.9 
4 190 4+4 54 45.9 
5 130 2+2 47 56.6 
 
The optimum temperature for the reaction in DMF was found between 130 and 
160 °C and this allowed us to obtain up to 57 % of incorporation of radioactivity 
in our ligand. 
[18F](R)-PK14105 will now be characterized with PET as a TSPO 18 kDa radiotracer 
in monkey. 
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Materials and Methods 
Routine nuclear magnetic resonance spectra were recorded in DMSO-d6 or 
CDCl3-d6 solution on a Bruker operating at 400 MHz. Evaporation was performed 
in vacuo (rotary evaporator). Analytical TLC was carried out on Merck 0.2 mm 
precoated silica gel aluminum sheets (60 F-254). Silica gel 60 (230-400 mesh) was 
used for column chromatography. Elemental analyses were performed by our 
analytical laboratory and agreed with theoretical values to within ±0.4%. 
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Methyl 4-bromonaphthalene-2-carboxylate 2. Methyl 1,2-dihydro-1-
oxoisoquinoline-3-carboxylate (0.5 mmol), potassium carbonate (2.0 mmol) and 
Phosphorus(V) oxybromide (1.9 mmol) were heated to reflux in dry aceto nitrile 
(10 ml). The reaction went to completion in 90 minutes. The resulting suspension 
was cooled to room temperature and then concentrated to dryness. The residue 
was cautiously dispersed in water and the insoluble material was filtered off, 
washed with water and dried. The product was utilized in the following reaction 
without any further purification.  
Yield: 61%; 1H-NMR (CDCl3-d6, ppm): 3.88 (s, 3H, OCH3); 7.93-7.84 (m, 3H, ArH); 
8.36  (s, 1H, ArH); 8.47 (d, 1H, J = 8.0 Hz, ArH). 
 
1-bromoisoquinoline-3-carboxylic acid 3. A solution of LiOH (13 mmol) in 10 ml 
of water was added to a stirred one of 2 (5 mmol) in 10 ml of anhydrous THF, and 
the mixture was allowed under stirring at room temperature for 60 minutes (TLC 
analysis). Then the mixture was acidified with HCl 6 N to pH=0 and the white 
precipitate was filtered off. The water was then extracted with CH2Cl2 and the 
resulting organic layer was dried over MgSO4. The combinated white precipitates 
were dried overnight.  
Yield: 85 % 
 
N-sec-butyl-1-bromoisoquinoline-3-carboxamide 4. Compound 3 (4 mmol) and 
1-Hydroxybenzotriazole hydrate (HOBt) (6 mmol) were mixed in a round bottom 
flask, under nitrogen, in dry CH2Cl2. Then, (R)-(−)-sec-Butylamine (12 mmol) and 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC)(12 mmol) 
were added and the reaction was stirred at room temperature overnight. 
Organic phase was washed twice with 10 % solution of NaHCO3, dried over 
MgSO4 and then evaporated. The product was finally purified by flash 
chromatography (hexane:AcOEt=1:1). 
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 Yield: 68 %; 1H-NMR (CDCl3-d6, ppm): 1.00 (t, 3H, J = 8.0 Hz, CH3); 1.31 (d, 3H, J = 
4.1 Hz, CH3); 1.68-1.63 (m, 2H, CH2); 4.19-4.15 (m, 1H, CH); 7.83-7.76 (m, 3H, 
ArH); 7.98 (d, 1H, ArH, J = 8.0 Hz,); 8.35  (d, 1H, ArH, J = 8.1 Hz). 
 
 
N-sec-butyl-1-bromo-N-methylisoquinoline-3-carboxamide 5. Sodium hydride 
(5.4 mmol) was added portionwise, under a nitrogen atmosphere, to an ice-
cooled solution of compound 4 in dry THF. After 30 minutes CH3I was added and 
the solution was stirred at 65 °C overnight. The solvent was eliminated under 
vacuum and the residue was diluited with water and extracted with AcOEt. The 
product was finally purified by flash chromatography (hexane:AcOEt=1:1). 
Yield: 70 %; 1H-NMR (CDCl3-d6, ppm): 1.01- 0.85 (2t, 3H, J = 4.1 Hz, J = 6.2 Hz, 
CH3); 1.31-1.24 (m, 3H, CH3), 1.70-1.58 1.48-1.42 (2m, 3H, CH3); 2.97, 2.91 (2s, 
3H, CH3); 4.79-4.75, 3.89-3.84 (2m, 1H, CH); 7.81-7.73 (m, 2H, ArH); 7.88  (d, 1H,  
J = 8.1 Hz, ArH); 7.98 (d, 1H, J = 8.0 Hz, ArH); 8.32 (d, 1H,  J = 8.1 Hz, ArH). 
 
N-sec-butyl-1-(5-fluoro-2-nitrophenyl)-N-methylisoquinoline-3-carboxamide 6. 
Compound 5 (10 mmol), 2-Fluoro-4-Nitro-boronic acid (25 mmol), cesium 
carbonate (25 mmol) and 1,1′-Bis(diphenylphosphino)ferrocene (1 mmol) were 
combinated in a round bottom flask under nitrogen atmosphere. Then 10 ml of 
degassed 2:1 dioxane: H2O were added and the reaction was stirred at 85 °C 
overnight. The solution was diluited with water, extracted with AcOEt, washed 
with brine, dried over MgSO4 and evaporated. The product was finally purified 
by flash chromatography (hexane:AcOEt=1:1). 
Yield: 65 %; 1H-NMR (CDCl3-d6, ppm): 1.00, 0.81 (2t, 3H, J = 6.1 Hz, J = 8.0 Hz, 
CH3); 1.34-1.24 (m, 3H, CH3); 1.72-1.59, 1.49-1.39 (2m, 2H, CH2); 3.00-2.82 (2s, 
3H, CH3); 4.86- 4.77, 3.93-3.84 (2m, 1H, CH); 7.42 (t, 1H, J = 10.0 Hz, ArH); 7.68-
7.63 (m, 1H, ArH); 7.81-7.73 (m, 2H, ArH); 8.04 (d, 1H, J = 8.1 Hz, ArH); 8.10 (d, 
1H, J = 12.0 Hz, ArH); 8.45-8.32 (m, 1H, ArH); 8.53-8.50 (m, 1H, ArH). 
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N-sec-butyl-1-(5-fluoro-2-(phenylthio)phenyl)-N-methylisoquinoline-3-
carboxamide 7. Compound 6 (0.46 mmol) was suspended in 18 ml of absolute 
ethanol. Then tiophenol (0.46 mmol) was added, following by KOH (0.7 mmol) in 
30 l of water. The reaction was manteined under stirring at room temperature 
until the disappearance of the starting material (TLC analysis). The solvent was 
eliminated under vacuum and the residue was dissolved in AcOEt, washed with 
water, dried over MgSO4 and then concentrated to dryness. The product was 
finally purified by flash chromatography (hexane:AcOEt=4:6).  
Yield: 70 %; 1H-NMR (CDCl3-d6, ppm): 1.01, 0.80 (2t, 3H, J = 8 Hz, J = 6.0 Hz, CH3); 
1.30-1.24 (m, 3H, CH3); 1.68-1.58, 1.45-1.40 (2m, 2H, CH2); 3.00-2.94 (2s, 3H, 
CH3); 4.84- 4.80, 3.99-3.96 (2m, 1H, CH); 7.13-7.05 (m, 1H, ArH); 7.44-7.38 (m, 
5H, ArH); 7.66-7.62 (m, 1H, ArH); 7.78-7.72 (m, 1H, ArH); 7.83-7.79 (m, 1H, ArH); 
8.00 (d, 1H, J = 8.0 Hz, ArH); 8.07 (s, 1H, ArH); 8.14-8.11 (m, 1H, ArH); 8.23-8.20 
(m, 1H, ArH) .  
 
N-sec-butyl-1-(5-fluoro-2-(phenylsulfinyl)phenyl)-N-methylisoquinoline-3 
carboxamide 8. meta-Chloroperoxybenzoic acid (0.15 mmol) was added to a 
solution of compound 7 in 5 ml of CH2Cl2. The reaction mixture was stirred for 2 
hours. Then, saturated acqueous solution of Na2SO3 was added and the organic 
phase was separated and washed with saturated acqueous solution of  NaHCO3. 
The combinated organic phase was dried over MgSO4 and concentrated to 
dryness. The product was finally purified by flash chromatography 
(hexane:AcOEt=4:6) 
 Yield: 55%; 1H-NMR (CDCl3-d6, ppm): 0.99-0.96, 0.80-0.73 (2m, 3H, CH3); 1.23-
1.16, 1.11 (m, d, J = 8.0 Hz, 3H, CH3); 1.64-1.53, 1.46-1.39 (2m, 2H, CH2); 2.99-
2.85 (s, d, J = 8.0 Hz, 3H, CH3); 4.81- 4.78, 3.95-3.68 (2m, 1H, CH) 7.15-7.07 (m, 
4H, ArH); 7.31-7.23 (m, 1H, ArH); 7.49-7.45 (m, 1H,  ArH); 7.75-7.70 (m, 1H, ArH); 
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7.97-7.92 (m, 1H, ArH); 8.10-8.04 (m, 1H, ArH); 8.32-8.29 (m, 1H, ArH); 8.56-8.42 
(m, 1H, ArH).  
 
Ethyl 4-bromoquinazoline-2-carboxylate 10. Compound ethyl 3,4-dihydro-4-
oxoquinazoline-2-carboxylate (2.3 mmol) and phosphorus tribromide (46 mmol) 
were placed in a round bottom flask to reflux at 180°C for 2-3 hours. The solution 
was poured into ice, alkalinized with NH4OH until pH=8-9, extracted with AcOEt, 
dried over  MgSO4, filtered and then evaporated to dryness. Crude compound 
was purified with flash chromatography (hexane:AcOEt=5:5) to give the desired 
product.  
Yield: 10-15%. 1H-NMR (CDCl3-d6, ppm): 1.52 (t, 3H, CH3, J= 7,2 Hz); 4.63 (q, 2H, 
CH2, J=10,2 Hz); 7.91-7.87 (m, 1H, ArH); 8.10-8.06 (m, 1H, ArH); 8.34-8.38 (m, 2H, 
ArH). 
 
Ethyl 4-(2-fluoro-5-nitrophenyl)quinazoline-2-carboxilate 11. Compound 10 (1.1 
mmol), (triphenylphosphine) Palladium (Tetrakis) (0.056 mmol) and potassium 
carbonate (2.2 mmol) were solubilized in anydrous toluene in a round bottom 
flask, under nitrogen. Then, 2-fluoro-5-nitrophenyl boronic acid (2.2 mmol) 
solubilized in 1 ml of absolute ethanol was added dropwise; the solution was 
heated at 100°C overnight. Solvents were eliminated under vacuum and the 
residue was dissolved in CH2Cl2, washed with water, dried over MgSO4, filtered 
and then concentrated to dryness. The product was finally purified by flash 
chromatography (hexane:AcOEt=6:4). 
Yield: 50%. 1H-NMR (CDCl3-d6, ppm): 1.52 (t, 3H, CH3, J= 7,2 Hz); 4.66 (q, 2H, CH2, 
J=10,2 Hz); 7.48 (t, 1H, ArH, J=8,8 Hz); 7.83-7.81 (m, 2H, ArH); 8.12-8.08 (m, 1H, 
ArH); 8.43 (d, 1H, ArH, J=8,4 Hz); 8.54-8.50 (m, 1H, ArH); 8.65-8.63 (m, 1H, ArH). 
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4-(2-fluoro-5-nitrophenyl)quinazoline-2-carboxylic acid 12. To a solution of 
compound 11 (0.35 mmol) in a mixture  MeOH/H2O 3:1, LiOH H2O (0.21 mmol) 
was added at 0°C. The solution was manteined under stirring at 80°C overnight. 
The solution was concentrated to dryness, the residue was solubilized in water 
and extracted in AcOEt. Water was acidified until pH=1 with HCl 10% then 
extracted with AcOEt, dried over MgSO4, filtered and at last concentrated to 
dryness.  
Yield= 68%. 
 
N-sec-butyl-4-(2-fluoro-5-nitrophenyl)quinazoline-2-carboxamide 13. A solution 
of 12 (0.24 mmol) in thionyl chloride (1.8 ml) was refluxed for 2 hours under 
nitrogen atmosphere. After cooling at room temperature, the excess thionyl 
chloride was removed at reduced pressure and the crude material dried under 
vacuum. To the residue, dissolved in dry THF (2ml) and cooled to 0 °C, a mixture 
of the (R)-sec-butylamine (0.24 mmol) and triethylamine (0.24 mmol) in dry THF 
(1.2 ml) was added dropwise. The mixture was stirred at room temperature for 
48 h, filtered, and evaporated. The crude residue was dissolved in CH2Cl2, 
washed with HCl 10%, saturated NaHCO3, and water, dried, and concentrated in 
vacuum. Purification by column chromatography on silica gel 
(hexane:AcOEt=5:5).73 
Yield=5%.  1H-NMR (CDCl3-d6, ppm): 0.99 (t, 3H, CH3, J= 7,4 Hz); 1.30 (d, 3H, CH3, 
J=6,4 Hz); 1.68-1.63 (m, 2H, CH2); 4.27-4.20 (m, 1H, CH); 7.17 (d, 1H, ArH J= 9,2 
Hz); 7.69-7.64 (m, 2H, ArH); 8.00-7.95 (m, 1H, ArH); 8.06 (bd, exch. with D2O, 1H, 
NH); 8.33 (d, 1H, ArH J=14 Hz); 8.38 (d, 1H, J=2,8 Hz); 8.48-8.46 (dd, 1H, ArH J=2,8 
Hz, J=2,8 Hz). 
 
Ethyl 4-(5-nitro-2-(phenylthio)phenyl)quinazoline-2-carboxylate 17. Compound 
10 (0.12 mmol) was suspended in 8 ml of absolute ethanol. Then tiophenol (0.12 
mmol) was added, following by KOH (0.1 mmol). The reaction was manteined 
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under stirring at room temperature until the disappearance of the starting 
material (TLC analysis). The solvent was eliminated under vacuum and the 
residue was dissolved in AcOEt, washed with water, dried over MgSO4 and then 
concentrated to dryness. The product was finally purified by flash 
chromatography (hexane:AcOEt=4:6). Two different products were obtained but 
neither of them was the desired compound. 
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